There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Galectin-3


Galectin-3 Molecule Information

Target Synonym:Galactose-specific lectin 3;Carbohydrate-binding protein 35;Mac-2 antigen;35 kDa lectin;Laminin-binding protein;GALBP;CBP 35;IgE-binding protein;Gal-3;L-31;MAC2;LGALS3;Galactoside-binding protein;Lectin L-29;Galectin-3
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved

Galectin-3 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
GA3-H5247 Human Human Galectin-3 Protein, His Tag
GA3-H5129 Human Human Galectin-3 Protein, His Tag

Galectin-3 Molecule Synonym Name

Galectin-3,LGALS3,MAC2,Gal-3,35 kDa lectin,CBP 35,GALBP,IgE-binding protein,L-31,Laminin-binding protein,Lectin L-29,Mac-2 antigen

Galectin-3 Molecule Background

Galectin-3 (Gal-3) is also known as LGALS3, 35 kDa lectin, Carbohydrate-binding protein 35 (CBP 35), Galactose-specific lectin 3, Galactoside-binding protein (GALBP), IgE-binding protein, Laminin-binding protein, Mac-2 antigen, Lectin L-29. Galectin-3 is a member of the lectin family. LGALS3 / Galectin-3 is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. LGALS3 / Galectin-3 has been shown to be involved in the following biological processes: cell adhesion, cell activation and chemoattraction, cell growth and differentiation, cell cycle, and apoptosis.

Galectin-3 References

Galectin-3 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ocriplasmin A-01016; THR-409 Approved ThromboGenics, Alcon JETREA fda Symptomatic vitreomacular adhesion THROMBOGENICS, INC 2012-10-17 Symptomatic vitreomacular adhesion Details

Galectin-3 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Gal-400 Gal-400,Gal400,Gal 400 Phase Ⅰ Galecto Biotech Hepatic fibrosis, Non-alcoholic steatohepatitis Details
Belapectin GR-MD-02 Phase Ⅲ Galectin Therapeutics, Providence Cancer Center Non-alcoholic steatohepatitis Details
TD-139 TD-139,TD139 Phase Ⅲ University of Edinburgh, Lund University, Bristol-Myers Squibb Idiopathic pulmonary fibrosis (IPF) Details
Galactomannan C GM-CT-01 NDA Filing Galectin Therapeutics Metastatic colorectal cancer (CRC) Details
GCS-100 GBC-590; GCS-100; GCS-100LE; LJPC-101; NCCG Phase Ⅱ La Jolla Renal failure, Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Prostate cancer, Colorectal cancer, Pancreatic cancer Details
LJPC-1010 Preclinical La Jolla Non-alcoholic steatohepatitis Details

This web search service is supported by Google Inc.